Understanding how amino acid availability affects T-cell function in tumors.
Official title: Identifying and Targeting Drivers of Impaired Translation in Tumor-infiltrating CD8+ T-cells.
Funded at Sloan-Kettering Inst Can Research · NIH-11250187 · Data updated 2026-11-12
This study is looking at how the availability of certain nutrients called amino acids affects the ability of important immune cells, called CD8+ T-cells, to fight cancer, with the goal of finding better ways to boost cancer treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | January 1, 2025 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $3,000 |
| NIH project number | 3F99CA294267-01S1 |
| Project ID | NIH-11250187 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients whose tumors are characterized by poor responses to immune checkpoint blockade therapies.
✕Less likely to help
Patients with tumors that are already responsive to immune checkpoint blockade therapies may not receive additional benefits from this research.
What this research studies
This research investigates the role of amino acid availability in the function of tumor-infiltrating CD8+ T-cells, which are crucial for anti-tumor immunity. The study aims to uncover how a lack of amino acids can lead to T-cell exhaustion, reducing their effectiveness in fighting cancer. By examining the mechanisms that limit T-cell function within the tumor microenvironment, the researchers hope to identify new strategies to enhance the efficacy of immune checkpoint blockade therapies. Patients may benefit from insights that could lead to improved cancer treatments targeting T-cell dysfunction.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that enhance T-cell responses in patients with tumors that currently do not respond to existing treatments.
How similar studies have gone: Other research has shown promise in understanding T-cell metabolism and its impact on cancer treatment, suggesting that this approach could lead to significant advancements.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Chen, Yan-Ting — Sloan-Kettering Inst Can Research
- Study coordinator: Chen, Yan-Ting
Related research
Other NIH-funded projects on the same topics.
-
Understand how skeletal muscle nuclei specialize and arrange themselves for proper muscle function
A study to uncover how the hundreds of nuclei in skeletal muscle fibers acquire different roles and positions to keep muscles strong and healthy.
-
Genomic profiling and outcomes of cancers in World Trade Center-exposed survivors and responders
This project looks at the genetic makeup and real-world cancer outcomes in people exposed to the World Trade Center disaster to understand how their cancers behave and respond to treatments.
-
Meaning-Centered Psychotherapy for Mexican Patients with Advanced Cancer
A cancer center in Mexico will test a culturally adapted therapy to help Mexican patients with advanced cancer find meaning, peace, and purpose at the end of life.
-
High-specificity genome-scale cell-surface proteomics to find tumor targets
A cancer research project is trying to map all the proteins on the surface of ultra-rare sarcoma cells to find safe, targeted ways to treat them.
-
Priorities for testing and choosing combination therapies in rhabdoid tumors to guide clinical trials
A coordinated, multi-site effort will rigorously test promising drug combinations in rhabdoid tumors to identify the most promising options for future patient trials.
-
ecDNA in Cancer: Understanding and targeting circular DNA that drives tumor growth
A cancer-focused project to understand how extrachromosomal DNA helps tumors grow and resist treatment, and to develop new ways to target these mechanisms.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.